0 item(s)
View cart
You have no items in your shopping cart.
$260.00
Sku: GMP-TL506-0050
Availability:
QUICK SHIP
In stock & estimated to ship in 1-2 days by June 06, 2026
Description
The recombinant human IL-7-Fc fusion protein is a glycosylated functional dimer produced in CHO expression systems, engineered with a C-terminal human IgG1 Fc domain to enhance protein stability and receptor clustering efficacy.
As a pivotal member of the IL-2 cytokine family, IL-7 activates the JAK1/JAK3-STAT5 signaling cascade via its heterodimeric receptor (IL-7Rα/γc), driving survival, proliferation, and differentiation of T/B/NK cells while maintaining lymphocyte homeostasis through Bcl-2-mediated anti-apoptotic mechanisms and promoting CD4+/CD8+ double-positive T-cell maturation during thymic development.
In cell therapy manufacturing, this fusion protein serves as a critical culture additive to enhance CAR-T cell metabolic fitness and memory phenotype formation through sustained PI3K-AKT-mTOR pathway activation. It synergizes with IL-15 to suppress exhaustion markers (e.g., PD-1/TIM-3) while supporting hematopoietic stem cell differentiation into functional lymphoid progenitors, thereby improving the persistence and antitumor efficacy of adoptive immune cell products.
The Fc-mediated dimeric configuration mimics native membrane-bound IL-7 bioactivity and optimizes pharmacokinetic profiles through extended serum half-life.
Specifications
| Cytokines Details | |
|---|---|
| Synonyms | Interleukin-7, IL-7 |
| Accession | UniProt P13232-1 |
| Expressed Region | Asp26–His177 |
| Fusion Tag | Human IgG1 Fc fragment fused to the C-terminus |
| Expression System | CHO cells |
| Predicted Molecular Weight | 43.8 kDa |
| Purity | > 95% as determined by SDS-PAGE and HPLC |
| Endotoxin | < 0.01 EU per 1 μg of protein (LAL method) |
| Biological Activity | Exhibits dose-dependent proliferation of PHA-activated PBMCs with an ED50 of 0.5–20 ng/mL and a specific activity > 1.0 × 107 IU/mg |
| Formulation | Lyophilized from sterile 20 mM phosphate-buffered saline (PBS), pH 7.4, typically containing 6–8% (w/v) mannitol as a stabilizing protectant |
Features
-
✔ High Biological Activity
Potently drives lymphocyte proliferation via IL-7Rα/γc–STAT5 signaling, validated by PBMC assays.
-
✔ Fc-Fusion Dimeric Design
Human IgG1 Fc fusion enhances protein stability, receptor clustering, and functional persistence.
-
✔ Excellent Batch Stability
GMP-compliant manufacturing ensures consistent purity, activity, and ultra-low endotoxin levels.
-
✔ DMF Filed (038126)
Supports regulatory readiness for cell and gene therapy development.
Applications
T Cell Expansion and Memory Formation
Enhances survival, metabolic fitness, and memory phenotype in CAR-T and T-cell cultures.
NK Cell Activation and Maintenance
Promotes NK cell proliferation and functional persistence in immunotherapy workflows.
Cell and Gene Therapy Manufacturing
Ideal as a cytokine supplement in GMP-aligned immune cell production processes.
Advanced Immunology Research
Suitable for studies requiring sustained IL-7 signaling and lymphocyte homeostasis control.
Data Figures
Stability & Storage
- Lyophilized powder: Stable for 12 months at -80°C or 6 months at -20°C when stored inthe original sealed container under desiccant.
- Reconstitution: Dissolve in sterile Water for Injection, 0.9% NaCl, or PBS (pH 7.4)maintaining final concentration ≥100 µg/mL to prevent adsorption.
- Handling: Aliquot to avoid repeated freeze-thaw cycles.
Cautions
• Research Use Only: This product is not intended for diagnostic or therapeutic use.
• Handling: Follow recommended storage and handling instructions to maintain product stability.
• Support: Contact technical support if assistance is required.
Documents
When can I expect my order to ship?
Most orders are filled and shipped within 2-3 business days from the time they are received.
Our standard shipping usually take 2-5 days.
We also provide express shippping for time-sensitive deliveries.
Email contact@biofargo.com if you have any requirements.
